In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D) For an adult with type 2 diabetes mellitus who requires substantial weight loss, what are the recommended use, dosing, regulatory approval status, and contraindications of tirzepatide compared with cagrilintide, and what alternative Caggrillintide Dosage TikTok Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased Retatrutide, Retatrutide vs. Tirzepatide, Retatrutide vs. Semaglutide, Retatrutide vs. Cagrilintide